STAT
OCTOBER 31, 2023
Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…
European Pharmaceutical Review
FEBRUARY 5, 2024
Congressman Greg Murphy highlighted that under the IRA price-fixing model, small molecule drugs are eligible for selection to the “Medicare Drug Price Negotiation” programme following seven years after US Food and Drug Administration (FDA) approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
OCTOBER 30, 2023
Lilly’s injectable drug Mounjaro reported favorable late-stage trial results in SURMOUNT-3 and SURMOUNT-4 and is forecasted to reach drug analyst consensus global forecast sales of $27.3 billion by 2029. Amgen witnessed the largest market capitalisation growth, fueled by its improved second-quarter earnings, revenue and $27.8
European Pharmaceutical Review
JANUARY 18, 2024
“The dominance of the US within the 7MM is due to its larger insomnia population and higher drug prices. GlobalData considered drug pricing and market exclusivity to be two major obstacles. GlobalData considered drug pricing and market exclusivity to be two major obstacles.
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. The primary manufacturer of a selected drug may also request CMS to terminate its agreement if they are unwilling to participate in the Medicare Drug Price Negotiation.
Pharmaceutical Technology
MAY 16, 2023
According to GlobalData’s drugs database pharma intelligence centre, Wegovy is expected to generate an analyst consensus global forecast sales of $9.4 million by 2029. Sanofi and Regeneron’s market capitalisation grew by 12.4%
Expert insights. Personalized for you.
330 
Let's personalize your content